KR910011812A - 염증성 장 질환 치료용 화합물 - Google Patents
염증성 장 질환 치료용 화합물 Download PDFInfo
- Publication number
- KR910011812A KR910011812A KR1019900021001A KR900021001A KR910011812A KR 910011812 A KR910011812 A KR 910011812A KR 1019900021001 A KR1019900021001 A KR 1019900021001A KR 900021001 A KR900021001 A KR 900021001A KR 910011812 A KR910011812 A KR 910011812A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- hydrogen
- integer
- alkenyl
- alkynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Eye Examination Apparatus (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Surgical Instruments (AREA)
- Nonmetallic Welding Materials (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 하기 일반식(Ⅱ)의 화합물 또는 그의 약학적으로 허용되는 염 :상기식에서, R1은 C2내지 C6알케닐, C2내지 C6알키닐 또는(여기서, n은 0과 3을 포함하는 0 내지 3의 정수이다)이고; R2는 수소, C1내지 C6알킬, C1내지 C6알콕시, C2내지 C6알케닐, C2내지 C6알키닐, C1내지 C4알킬(C1내지 C4알킬) 또는(여기서 n은 0과 3을 포함하는 0 내지 3의 정수이다)이며; R3는 수소 또는 C1내지 C6알킬이고; R4및 R5는 각각 수소이거나 또는 함께 결합을 형성하며; R6및 R7은 각각 수소이거나 또는 함께 =S이거나, 또는 R6및 R7중 하나가 수소이면 다른 하나는 -OH 또는 -SCH3이고; X는(여기에서, m은 0,1 또는 2이다)이며; Q는 -CH2- -O- 또는 NR8[여기에서, R8은 수소, C1내지 C6알킬, C2내지 C6알케닐, C3내지 C8사이클로알킬, -SO2CH3또는 -(CH2)n-Y이고, 이때 n은 0과 3을 포함하는 0 내지 3의 정수이며 Y는 시아노, OR9,테트라졸릴, -NR11R12, -SH, -S(C1내지 C4알킬)또는알킬 이고, R9는 수소, C1내지 C4알킬, 또는내지 C4알킬이고, R10은 C1내지 C4알킬, C1내지 C4알콕시 또는 -NH2이며, R11및 R12는 각각 독립적으로 수소, C1내지 C6알킬, C2내지 C6알케닐, C2내지 C6알키닐, -(CH2)qOH, -(CH2)q-N(C1내지 C4알킬)2, -(CH2)q-S(C1내지 C4알킬)또는(여기서, n은 상기에 정의한 바와 같으며, q는 1과 6을 포함하는 1 내지 6의 정수이다)이거나, 또는 R11및 R12는 함께 모르폴리닐, 피페리디닐, 피페라지닐 또는 N-메틸피페라지닐 고리를 형성한다]이다.
- 제1항에 있어서, R1이 C2내지 C6알케닐, C2내지 C6알키닐 또는(여기서, n은 0과 3을 포함하는 0내지 3의 정수이다)이고; R2가 수소, C1내지 C6알킬, C1내지 C6알콕시, C2내지 C6알케닐, C2내지 C6알키닐, 또는(여기서, n은 0과 3을 포함하는 0내지 3의 정수이다)이며; R3가 소수 또는 C1내지 C6알킬이고; R4및 R5가 각각 수소이거나 또는 함께 결합을 형성하며; R6및 R7이 각각 수소이거나 또는 함께 =S이거나, 또는 R6및 R7중 하나가 수소이면 다른 하나는 -OH 또는 -SCH3이고; X가(여기에서, m은 0,1 또는 2이다)이며; Q가 -CH2-, -O- 또는 NR8[여기에서, R8은 수소, C1내지 C6알킬, C3내지 C8사이클로알킬, -SO2CH3또는 -(CH2)n-Y이고, 이때 n은 0과 3를 포함하는 0 내지 3의 정수이며 Y는 시아노, OR9,테트라졸릴, -NR11R12, 또는알킬이고, R9는 수소, C1내지 C4알킬, 또는내지 C4알킬이고; R10은 C1내지 C4알킬, C1내지 C4알콕시 또는 -NH2이며, R11및 R12가 각각 독립적으로 수소, C1내지 C6알킬, -(CH2)qOH- (CH2)q-N(C1내지 C4알킬)2, -(CH2)q-S(C1내지 C4알킬) 또는(여기에서, n은 상기에 정의한 바와 같으며, q는 1과 6을 포함하는 1 내지 6의 정수이다)이거나, 또는 R11및 R12는 함께 모르폴리닐, 피페리디닐, 피페라지닐 또는 N-메틸피페라지닐 고리를 형성한다]인 화합물 또는 그의 약학적으로 허용되는 염.
- 활성 성분으로서, 제1항 또는 제2항의 화합물, 또는 그의 약학적으로 허용되는 염과 함께 약학적으로 허용되는 희석제, 부형제 또는 담체 하나 이상을 포함하는 약학 조성물.
- 염증성 장 질환의 치료에 사용하기 위한 제1항 또는 제2항의 화합물.
- 염증성 장 질환 치료용 약물을 제조하기 위한 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용되는 염의용도:상기식에서, R1및 R2는 각각 독립적으로 수소, C1내지 C6알킬, C1내지 C6알콕시, C2내지 C6알케닐, C2내지 C6알키닐, C1내지 C4알킬(C1내지 C4알킬)또는(여기서, n은 0과 3을 포함하는 0내지 3의 정수이다)이고; R3는 수소 또는 C1내지 C6알킬이고; R4및 R5는 각각 수소이거나 또는 함께 결합을 형성하며; R6및 R7는 각각 수소이거나 또는 함께 =S이거나, 또는 R6및 R7중 하나가 수소이면 다른 하나는 -OH 또는 -SCH3이고; X는(여기에서, m은 0,1 또는 2이다)이며; Q는 -CH2-, -O- 또는 NR8[여기에서, R8은 수소, C1내지 C6알킬, C2내지 C6알케닐, C3내지 C8사이클로알킬, -SO2CH3또는 -(CH2)n-Y이고, 이때 n은 0과 3을 포함하는 0 내지 3의 정수이며 Y는 시아노, OR9,테트라졸릴, -NR11R12, -SH,-S(C1내지 C4알킬) 또는알킬이고, R9는 수소, C1내지 C4알킬, 또는내지 C4알킬이고, R10은 C1내지 C4알킬, C1내지 C4알콕시 또는 -NH2이며, R11및 R12는 각각 독립적으로 수소, C1내지 C6알킬, C2내지 C6알케닐, C2내지 C6알키닐, -(CH2)qOH, -(CH2)q-N(C1내지 C4알킬)2, -(CH2)q-S(C1내지 C4알킬) 또는(여기서, n은, 상기에 정의한 바와 같으며, q는 1과 6을 포함하는 1 내지 6의 정수이다)이거나, 또는 R11및 R12는 함께 모르폴리닐, 피페리디닐, 피페라지닐 또는 N-메틸피페라지닐 고리를 형성한다]이다.
- 제5항에 있어서, R1및 R2가 각각 독립적으로 수소, C1내지 C6알킬, C1내지 C6알콕시, C2내지 C6알케닐, C2내지 C6알키닐, 또는(여기서, n은 0과 3을 포함하는 0 내지 3의 정수이다)이고; R3과 수소 또는 C1내지 C6알킬이고; R4및 R5가 각각 수소이거나 또는 함께 결합을 형성하며; R6및 R7이 각각 수소이거나 또는 함께 =S이거나, 또는 R6및 R7중 하나가 수소이면 다른 하나는 -OH 또는 -SCH3이고; X가(여기에서, m은 0,1 또는 2이다)이며; Q가 -CH2-, -O- 또는 NR8[여기에서, R8은 수소, C1내지 C6알킬, C3내지 C8사이클로알킬, -SO2CH3또는 -(CH2)n-Y이고, 이때 n은 0과 3을 포함하는 0 내지 3의 정수이며 Y는 시아노, OR9,테트라졸릴, -NR11R12, 또는알킬이고, R9는 수소, 또는내지 C4알킬 C1내지 C4알킬이고, R10은 C1내지 C4알킬, C1내지 C4알콕시 또는 -NH2이며, R11및 R12는 각각 독립적으로 수소, C1내지 C6알킬, -(CH2)qOH, -(CH2)q-N(C1내지 C4알킬)2, -(CH2)q-S(C1내지 C4알킬) 또는(여기서, n은 상기에 정의한 바와 같으며, q는 1과 6을 포함하는 1내지 6의 정수이다) 이거나, 또는 R11및 R12는 함께 모르폴리닐, 피페리디닐, 피페라지닐 또는 N-메틸피페라지닐 고리를 형성한다]인 화합물 또는 그의 약학적으로 허용되는 염의 염증성장 질환 치료용 약물을 제조하기 위한 용도.
- 염증성 잘 질환 치료용 약물을 제조하기 위한 5-[[3,5-비스(1,1-디메틸에틸) -4-하이드록시페닐]메틸]-4-티아졸리디논의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45420389A | 1989-12-21 | 1989-12-21 | |
US7/454203 | 1989-12-21 | ||
US07/454203 | 1989-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR910011812A true KR910011812A (ko) | 1991-08-07 |
KR0176243B1 KR0176243B1 (ko) | 1999-03-20 |
Family
ID=23803709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900021001A KR0176243B1 (ko) | 1989-12-21 | 1990-12-19 | 염증성 장 질환 치료용 화합물 |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0434394B1 (ko) |
JP (1) | JP3036853B2 (ko) |
KR (1) | KR0176243B1 (ko) |
CN (1) | CN1029846C (ko) |
AT (1) | ATE169294T1 (ko) |
AU (1) | AU639734B2 (ko) |
CA (1) | CA2032330C (ko) |
CY (1) | CY2100B1 (ko) |
DE (1) | DE69032537T2 (ko) |
DK (1) | DK0434394T3 (ko) |
ES (1) | ES2121748T3 (ko) |
FI (2) | FI104251B1 (ko) |
HU (1) | HU216732B (ko) |
IE (1) | IE904633A1 (ko) |
IL (3) | IL108962A (ko) |
MX (1) | MX23803A (ko) |
NO (1) | NO300458B1 (ko) |
NZ (1) | NZ236472A (ko) |
PT (1) | PT96198B (ko) |
RU (2) | RU2036915C1 (ko) |
YU (1) | YU240690A (ko) |
ZA (1) | ZA9010041B (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU87339A1 (fr) * | 1988-09-20 | 1990-04-06 | Oreal | Nouveaux derives de benzylidene-cyclanones,leur procede de preparation,leur utilisation en tant qu'agents anti-oxydants et comme filtres solaires,compositions cosmetiques et pharmaceutiques les contenant |
US5143928A (en) * | 1990-03-27 | 1992-09-01 | Warner-Lambert Company | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents |
ZA936492B (en) * | 1992-09-10 | 1995-03-02 | Lilly Co Eli | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease. |
DK0595546T3 (da) * | 1992-10-28 | 1996-04-15 | Shionogi & Co | Benzylidenderivater |
US6251928B1 (en) | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
US5563277A (en) * | 1994-12-21 | 1996-10-08 | Eli Lilly And Company | Process for preparing benzyl-substituted rhodanine derivatives |
EP0761657B1 (en) * | 1995-09-07 | 2000-05-24 | Eli Lilly And Company | Process for preparing benzyl-substituted rhodanine derivatives |
IN182320B (ko) * | 1995-09-07 | 1999-03-20 | Lilly Co Eli | |
EP0779282A1 (en) * | 1995-12-14 | 1997-06-18 | Eli Lilly And Company | Thiomorpholinone compounds for treating multiple sclerosis |
US5981523A (en) * | 1996-02-05 | 1999-11-09 | Eli Lilly And Company | Compounds and methods for treating multiple sclerosis |
US6063799A (en) * | 1996-09-03 | 2000-05-16 | Eli Lilly And Company | Alternate crystal form of Tazofelone |
US6005142A (en) | 1996-09-03 | 1999-12-21 | Eli Lilly And Company | Process for preparing benzyl-substituted rhodanine derivatives |
WO2000018746A1 (en) * | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
EP1117655A1 (en) | 1998-09-30 | 2001-07-25 | Angelika Esswein | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders |
AU6330999A (en) * | 1998-09-30 | 2000-04-17 | Roche Diagnostics Gmbh | Rhodanine derivatives for the treatment and prevention of metabolic bone disorders |
US7235573B2 (en) | 2002-09-30 | 2007-06-26 | The Regents Of The University Of California | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors |
NZ538809A (en) * | 2002-09-30 | 2008-06-30 | Univ California | Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
AU2002953533A0 (en) | 2002-12-24 | 2003-01-16 | Arthron Limited | Fc receptor modulating compounds and compositions |
JP5778755B2 (ja) * | 2010-04-15 | 2015-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | ヒドロキノンの製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1285572C (en) * | 1985-08-09 | 1991-07-02 | Jill Ann Panetta | Di-t-butylphenol compounds |
IE62214B1 (en) * | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
DE69027472T2 (de) * | 1989-04-07 | 1996-12-05 | Lilly Co Eli | Arylsubstituierte Rhodaninderivate |
-
1990
- 1990-12-13 IL IL10896290A patent/IL108962A/en not_active IP Right Cessation
- 1990-12-13 IL IL9665490A patent/IL96654A/en not_active IP Right Cessation
- 1990-12-13 ZA ZA9010041A patent/ZA9010041B/xx unknown
- 1990-12-14 NZ NZ236472A patent/NZ236472A/xx unknown
- 1990-12-14 CA CA002032330A patent/CA2032330C/en not_active Expired - Fee Related
- 1990-12-14 PT PT96198A patent/PT96198B/pt active IP Right Grant
- 1990-12-19 KR KR1019900021001A patent/KR0176243B1/ko not_active IP Right Cessation
- 1990-12-19 AU AU68266/90A patent/AU639734B2/en not_active Ceased
- 1990-12-19 FI FI906273A patent/FI104251B1/fi not_active IP Right Cessation
- 1990-12-19 EP EP90313923A patent/EP0434394B1/en not_active Expired - Lifetime
- 1990-12-19 DE DE69032537T patent/DE69032537T2/de not_active Expired - Fee Related
- 1990-12-19 ES ES90313923T patent/ES2121748T3/es not_active Expired - Lifetime
- 1990-12-19 AT AT90313923T patent/ATE169294T1/de not_active IP Right Cessation
- 1990-12-19 MX MX2380390A patent/MX23803A/es unknown
- 1990-12-19 NO NO905478A patent/NO300458B1/no not_active IP Right Cessation
- 1990-12-19 DK DK90313923T patent/DK0434394T3/da active
- 1990-12-20 YU YU240690A patent/YU240690A/sh unknown
- 1990-12-20 JP JP2413313A patent/JP3036853B2/ja not_active Expired - Fee Related
- 1990-12-20 RU SU904894177A patent/RU2036915C1/ru active
- 1990-12-20 IE IE463390A patent/IE904633A1/en not_active Application Discontinuation
- 1990-12-20 CN CN90109846A patent/CN1029846C/zh not_active Expired - Fee Related
- 1990-12-20 HU HU908368A patent/HU216732B/hu not_active IP Right Cessation
-
1991
- 1991-12-24 RU SU915010352A patent/RU2050355C1/ru active
-
1994
- 1994-03-14 IL IL10896294A patent/IL108962A0/xx unknown
-
1998
- 1998-09-07 CY CY9800024A patent/CY2100B1/xx unknown
-
1999
- 1999-08-10 FI FI991698A patent/FI19991698A/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910011812A (ko) | 염증성 장 질환 치료용 화합물 | |
KR890006603A (ko) | 항균제로 유용한 아미노메틸 옥소옥사졸리디닐 에테닐벤젠 유도체 | |
ATE79376T1 (de) | Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
ATE67496T1 (de) | Thiazolidinderivate, verfahren zu deren herstellung und deren anwendung. | |
KR950702982A (ko) | 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives) | |
DE3271269D1 (en) | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same | |
ATE74352T1 (de) | Dekahydrochinolinderivate, verfahren zu ihrer herstellung, zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende zubereitungen. | |
AU7582094A (en) | New 1,2,3,4-tetrahydronaphthalene compounds, process for their preparation and the pharmaceutical compositions which contain them | |
KR940003953A (ko) | 1. 4-벤조디옥산 유도체 | |
FR2709306B1 (fr) | Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
HUT50337A (en) | Process for producing benzoxazine derivatives and pharmaceutical compositions comprising the compounds | |
KR910006309A (ko) | 인지질 및 인지질 유도체를 유효 성분으로 하는 항비루스성 약제 | |
KR880003941A (ko) | 4,5-디하이드로옥사졸 유도체, 그의 제조방법 및 용도 | |
IE901314L (en) | 2- substituted-n,n'-di(trimethoxybenzoyl)piperazines | |
KR960017669A (ko) | 양쪽성 3환식 화합물 | |
KR900001665A (ko) | 사이클로알킬티아졸 유도체 | |
ZA905650B (en) | Method of treating diabetes mellitus | |
DE69021664D1 (de) | Verwendung von bisphenol-Derivaten zur Behandlung von Diabetes mellitus. | |
ATE52509T1 (de) | Thiazolidinderivate und verfahren zu ihrer herstellung. | |
ATE29133T1 (de) | Troponon-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung. | |
OA09471A (fr) | "Nouvelles benzothiazolinones substituées, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent". | |
DE3784883T2 (de) | Fluor enthaltende makrolid-verbindungen, pharmazeutische zusammensetzungen, welche diese enthalten und ihre verwendung fuer die herstellung von arzneimitteln. | |
KR900014307A (ko) | 뇌혈관성 질환 치료용 다환식 아민류 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20010109 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |